Boehringer Ingelheim

Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.

One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.

A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.

6701 Kaiser Drive
Fremont, CA 94555 US
NEWS
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
The AMR Action Fund is ramping up its infrastructure – announcing yesterday that former Novartis Venture Funds Head, Henry Skinner, will take the helm as the organization’s first chief executive officer.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
Boehringer Ingelheim’s Animal Health USA division will reimburse $379,089 in back pay and interest to 75 female employees to resolve alleged wage discrimination at its St. Joseph, Missouri, facility.
It was a very busy week for clinical trial updates. Here’s a look.
Boehringer Ingelheim and Eli Lilly and Company announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
The U.S. Food and Drug Administration issued a Completed Response Letter of Eli Lilly and Company and Boehringer Ingelheim’s Jardiance (empaglifozin) for type 1 diabetes.
FDA
The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Ofev (nintedanib) for patients with chronic fibrosing interstitial lung diseases with a progressive phenotype.
JOBS
IN THE PRESS